AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05958290 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Discontinuation of antibiotics
Description: Discontinuation of antibiotic treatment after at least 10 days iv antibiotic therapy and then per oral treatment to at least 6 weeks total.
Study NCT05771324 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Baby-Led Weaning (BLW)
Description: BLW trainings given to mothers for 6-12 month old babies
Study NCT05771324 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Traditional Complementary Feeding (TCF)
Description: TCF trainings given to mothers for 6-12 month old babies
Study NCT06299878 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Gut microbiota analysis
Description: Patients with resectable stage IIIB-D melanoma will have a lymph node core biopsy to confirm metastatic lesions, following standard procedures. Additionally, a portion of the tumor tissue will be preserved for biomarker analysis. Participants will then be instructed to submit fecal samples and complete a dietary questionnaire before receiving three doses of PD1 monotherapy, in accordance with the center\&#39;s routine practice, typically spanning 6-10 weeks. Between weeks 10 and 12, a radiological assessment of the response will be conducted. Following this, participants will undergo regional lymphadenectomy, and the pathological response will be evaluated. After surgery, patients will be placed on adjuvant therapy for 12 months as per routine practice of the center . Subsequently, they will be monitored for five years, adhering to the institution\&#39;s standard follow-up protocol.
Study NCT05729750 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Trans abdominal ultrasound for assess biophysical profile
Description: The biophysical profile (BPP) was developed as a method of integrating real-time observation of the fetus in an intrauterine environment. Manning et al introduced the BPP test in 1980, and since then it has been widely used as a comprehensive assessment tool for both acute and chronic fetal health and fetal congenital malformations in the antepartum period which is a method that uses an overview of 5 key indicators, namely fetal tone, fetal breathing, fetal movement, deep ventricular pocket and NST, thus making it more accurate than either viewing.
Study NCT05729750 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: Trans abdominal ultrasound for assess biophysical profile
Description: The biophysical profile (BPP) was developed as a method of integrating real-time observation of the fetus in an intrauterine environment. Manning et al introduced the BPP test in 1980, and since then it has been widely used as a comprehensive assessment tool for both acute and chronic fetal health and fetal congenital malformations in the antepartum period which is a method that uses an overview of 5 key indicators, namely fetal tone, fetal breathing, fetal movement, deep ventricular pocket and NST, thus making it more accurate than either viewing.
Study NCT05465915 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Electroconvulsive therapy
Description: Patients are treated with ECT.
Study NCT05747079 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rehabilitation
Description: All patients complete rehabilitation under supervision of their own physiotherapist. The investigators will provide some guidelines and criteria, but it is the physiotherapist's choice how to implement these guidelines in clinical practice.
Study NCT06562894 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SYHX1901
Description: Administered orally, once daily (QD)
Study NCT05747079 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Optional delayed anterior cruciate ligament reconstruction
Description: If a patient complains about persistent symptomatic instability of the knee or the inability to progress in rehabilitation, delayed surgery can be considered. ACL insufficiency induced instability in combination with a positive pivot shift and an additional MRI are needed to confirm the cause of instability.~This surgery will not be performed within the first 12 weeks after the ACL injury.
Study NCT05747079 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Immediate anterior cruciate ligament reconstruction
Description: No guidelines on type of ACL reconstruction will be imposed to keep the trial pragmatic. The decision of graft type and surgery technique is a clinical decision made by the orthopaedic surgeons of the participating centra.~This surgery will be performed within 12 weeks after the ACL injury.
Study NCT05128227 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pharm-SAVES
Description: A 30 minute long online module with videos and didactic content that covers the following topics: warning signs of suicide, how to ask a patient if they are contemplating suicide, and how to refer a patient to the Crisis Line. Three videos model patient scenarios of suicidal behavior in pharmacy settings including the pharmacy drive through, over the phone, and in person. Participants will receive continuing education credits (CEUs) (0.1 CEUs) for completing the course.
Study NCT05128227 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Pharm-SAVES
Description: A 30 minute long online module with videos and didactic content that covers the following topics: warning signs of suicide, how to ask a patient if they are contemplating suicide, and how to refer a patient to the Crisis Line. Three videos model patient scenarios of suicidal behavior in pharmacy settings including the pharmacy drive through, over the phone, and in person. Participants will receive continuing education credits (CEUs) (0.1 CEUs) for completing the course.
Study NCT05128227 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interactive video cases
Description: Two video interactive cases (approximately 10-minutes combined total) ask participants to complete open and close-ended questions about patients who exhibit suicidal behavior at the pharmacy. Participants will receive continuing education credits (0.1 CEUs) for completing the course.
Study NCT06562894 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally, once daily (QD)
Study NCT05277727 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fucoidan 500mg
Description: 1 capsule to be taken twice daily with food (morning and evening).
Study NCT05277727 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 capsule to be taken twice daily with food (morning and evening).
Study NCT05432154 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Film forming silicone gel (7-0940)
Description: Film forming silicone gel (7-0940) is an innovative gel that forms a full contact, flexible wound dressing for supporting mucosal conditions of the genital, rectal and perineal areas.~Film forming silicone gel (7-0940) is a semi-occlusive, non-resorbable, self-drying and transparent gel.~Film forming silicone gel (7-0940) may be directly applied to dry, wet, cracked and sensitive mucosal tissue.~Film forming silicone gel (7-0940) gel is bacteriostatic and inert. It contains no alcohols, parabens or fragrances.
Study NCT05505877 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BR790+Tislelizumab
Description: BR790 will be administered orally, variable dose.~Tislelizumab will be administered as an intravenous infusion,fixed dose.
Study NCT05152173 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: EN3835
Description: Participant will receive a maximum dose of up to1.8mg of EN3835 injection
Study NCT05152173 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participant will receive a maximum dose of up to1.8mg of Placebo injection
Study NCT05665933 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ACCEPTANCE AND COMMITMENT THERAPY-BASED PSYCOEDUCATION
Description: Total Duration: 6 Weeks Session Duration: 90 min Frequency: 1 day per week Number of People: 30
Study NCT05796466 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: How-to talk so kids will listen and listen so kids will talk
Description: The How-to Parenting Program focuses on how expectations, rules, and values are better communicated (vs. what rules ought to be). It includes skills related to the three components of authoritative parenting, namely affiliation, structure, and autonomy support. 1) Affiliation: Parents learn how to listen and respond to their children in a way that helps them feel accepted unconditionally. 2) Structure: Parents learn how to communicate expectations, give feedback, follow through, and use joint problem-solving in a factual, non-judgmental way. 3) Autonomy support: Parents learn how to validate emotions, encourage initiatives, and free children from roles. Finally, the How-to program can be endorsed by parents of various cultural backgrounds, as suggested by the large number (> 30) of languages in which the material is translated. This advantage is crucial in ethnically diverse regions such as Canada.
Study NCT05322148 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Klarity CL, Cylcosporine 0.1%/Loteprednol Etabonate 0.2% Preservative Free
Description: A number of studies have shown the benefit of both cyclosporine and steroids in managing dry eye. However, existing formulations of these products are challenged by either limited tolerability, a high out-of-pocket cost or both. Combination therapy with these agents in an advanced, more tolerable formulation have the potential to improve both tolerability and cost. However, the available formulation of preservative free Klarity CL (cyclosporine 0.1% and loteprednol 0.2% in a chondroitin sulfate vehicle) has not been studied rigorously.
Study NCT05929469 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: App
Description: Participants will receive an mHealth program.
Study NCT05796466 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Nobody's Perfect
Description: Nobody's Perfect is delivered in family resource centers across Canada to support parents of infants and preschoolers. Its focus is on developing parents' capacity to problem solve, providing child development information, and helping parents recognize their strengths and find their own positive ways to interact with their children. It thus does not teach specific parenting skills and does not suggest specific rules to put into practice in the home-environment.
Study NCT05802407 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Later-line therapy
Description: Another chemotherapy regimen, targeted therapy, or immunotherapy
Study NCT05929469 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fully Automated Kick-Off
Description: As an orientation to the study, participants will receive a fully automated kick-off session.
Study NCT05929469 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Human-Enhanced Kick-Off
Description: As an orientation to the study, participants will receive a kick-off session that includes time with a study interventionist.
Study NCT05929469 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Check-In
Description: Participants will receive a check-in with a study interventionist.
Study NCT05929469 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Counseling
Description: Participants will receive counseling from a study interventionist.
Study NCT05756972 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PM8002
Description: IV infusion
Study NCT05756972 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: IV infusion
Study NCT05756972 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: IV infusion
Study NCT05756972 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: IV infusion
Study NCT03987841 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Integrated MBSR/DSME intervention
Description: Integrated mindfulness-based stress reduction/diabetes self-management education intervention. The intervention will comprise components of MBSR and DSME and will be delivered in a group setting with 8 weekly sessions. A trained masters-level interventionist will deliver the integrated intervention.
Study NCT06544343 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Remote Monitoring
Description: Follow-up at outpatient clinic at 3 and 6 months from drug prescription Two remote consultations at 15 and 45 days from drug prescription
Study NCT06544343 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: On site monitoring
Description: Follow-up at outpatient clinic at 3 and 6 months from drug prescription.
Study NCT05210855 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: CT scan
Description: Scan with classic dose followed by ultra-low dose
Study NCT06139757 — intervention group
Intervention type: DEVICE
Intervention: Oura ring
Description: Patient will wear Oura ring before and after embryo transfer. They will be blinded to sleep data during this period. Thus the intervention of wearing the ring to track sleep will not affect outcomes, but rather track the outcome of sleep.
Study NCT06267885 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cannulated screws vs wagner's technique
Description: Fixation of fracture neck of femur by cannulated screws or wagner's technique
Study NCT06544343 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: On site monitoring
Description: Follow-up at outpatient clinic at 3 and 6 months from drug prescription.
Study NCT05635045 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: I 124-Evuzamitide
Description: Amyloid reactive protein used as imaging agent in whole body SPECT-CT imaging
Study NCT04769466 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: LifeBio Memory
Description: LifeBio Memory is a digital reminiscence therapy platform designed to collect the life stories of older adults to generate personalized life storybooks that capture their unique narratives and social histories. Life story booklets, summaries, and materials are also developed as mechanisms for sharing this story and for staff to provide enhanced person-centered care.
Study NCT05561309 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HR18034;Ropivacaine Hydrochloride Injection
Description: Drug: HR18034~Drug: Ropivacaine Hydrochloride Injection~Local nerve block of Ropivacaine Hydrochloride Injection to produce anesthesia for surgery and analgesia in postoperative pain management.~Other Name: Ropivacaine Hydrochloride Injection, 0.5% Injectable Solution
Study NCT05887505 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: Oral supplementation of 576,000IU/day vitamin D3 in 3 consecutive days
Study NCT05887505 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral supplementation of placebo in 3 consecutive days.
Study NCT05077137 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tetanus Diptheria Vaccine
Description: tetanus and diphtheria toxoids
Study NCT05037149 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STP707
Description: STP707 Powder for Injection
Study NCT05077137 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Polio Boost Immunization
Description: trivalent inactivated polio vaccine
Study NCT06433778 — intervention group
Intervention type: OTHER
Intervention: No Intervention
Description: This is a non-interventional study.
Study NCT06584448 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Deuterium Metabolic Imaging with deuterated acetate tracer
Description: Deuterium Metabolic Imaging (DMI) is a method by which Magnetic Resonance Spectroscopy (MRS) is used to map the appearance of deuterium from a tracer source (e.g., deuterated acetate) in products of metabolism. In this case we will map the combination of glutamate and glutamine, called Glx, to serve as a tag to measure the brain's rate of acetate consumption. That is, the more deuterium appears in Glx, the more acetate that part of the brain consumes.
Study NCT06500819 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: B7-H3CART Dose (Intravenous)
Description: Subjects who meet cell infusion eligibility will receive IV B7-H3CART cells on Day 0.~Dose level -1 (DL-1) 0.3 x 106 transduced T cells/kg~Subjects who meet cell infusion eligibility will receive IV B7-H3CART cells on Day 0.~Dose level 1 (DL1) 1 x 106 transduced T cells/kg~Subjects who meet cell infusion eligibility will receive IV B7-H3CART cells on Day 0.~Dose level 2 (DL2) 3 x 106 transduced T cells/kg~Subjects who meet cell infusion eligibility will receive IV B7-H3CART cells on Day 0.~Dose level 2 (DL2) 3 x 106 transduced T cells/kg~Subjects who meet cell infusion eligibility will receive IV B7-H3CART cells on Day 0.~Dose level 3 (DL3) 9 x 106 transduced T cells/kg
Study NCT03909347 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PLAN
Description: The study intervention, PLAN is a multifaceted intervention led by trained CHW. It consists of two main components: dementia literacy education and phone counseling with navigation assistance through (1) 1-hour visit for dementia literacy education and (2)monthly counseling with navigation assistance
Study NCT03909347 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: The investigators will refer control group participants to participants' primary physicians for follow-up and provide an Alzheimer's Association brochure about signs of dementia and dementia treatment, which is publicly available in Korean.
Study NCT05287126 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etrasimod
Description: Etrasimod tablet by mouth, once daily up to 52 weeks of treatment.
Study NCT06571422 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WJ47156
Description: Monotherapy study: participate will recepit WJ47156 monotherpy with 3 dose groups; Combination therapy study: participate will recepit WJ47156 and other study drug if in the combination therapy period
Study NCT06571422 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JS001+Bevacizumab
Description: Participants in Cohort1 of combination therapy phase will receive WJ47156 plus toripalimab and bevacizumab.Toripalimab and bevacizumab are administered intravenously.
Study NCT06580717 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: enavogliflozin 0.3mg
Description: Enavogliflozin 0.3mg, 1 tablet once a day, is prescribed for a period of 24 weeks.~Patients who are eligible for all of the criteria and who do not qualify as exclusion criteria should be enrolled in the study and randomly enrolled in a 1: 1 dose of enavogliflozin 0.3 mg once daily or placebo.
Study NCT06580717 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: enavogliflozin Placebo
Description: A placebo pill identical to enavogliflozin, 1 tablet once a day, is prescribed for a period of 24 weeks.~Patients who are eligible for all of the criteria and who do not qualify as exclusion criteria should be enrolled in the study and randomly enrolled in a 1: 1 dose of enavogliflozin 0.3 mg once daily or placebo.
Study NCT05114096 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celestone + placebo
Description: After the first intramuscular injection of Celestone, participants randomized to the Placebo Comparator group will receive 1 intramuscular injection of placebo.
Study NCT05114096 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Celestone + Celestone
Description: After the first intramuscular injection of Celestone, participants randomized to the Active Comparator group will receive 1 intramuscular injection of Celestone.
Study NCT03777137 — intervention group
Intervention type: BEHAVIORAL
Intervention: TMS (Rapid2, Magstim Corp)
Description: Volunteers will take a telephone screening questionnaire and those meeting inclusion criteria will attend their first visit. Those signing the consent will have a T1 weighted MRI scan to localize sites in the brain to be stimulated with TMS. The subjects will then have four visits at intervals of two weeks; each visit will have a TMS intervention including SITE1, SITE2, SITE3, and SITE4. The sequence of the testing TMS four different visits (SITE1 to SITE4) will be randomly assigned among stimulation sites Medial Frontal (MF), Dorsal Lateral Frontal (DL), Primary motor cortex (M1) and Interparietal Sulcus (Sham) and counterbalanced across subjects (see Diagram below). During each of visits 2 to 5, each participant will undergo baseline Quantitative Sensory Testing (QST), followed by a TMS intervention, and then by repeat QST. QST will consist of pain thresholds for contact heat.
Study NCT04968210 — intervention group
Intervention type: DRUG
Intervention: Hyperpolarized 13C-pyruvate
Description: Use of hyperpolarized 13C-pyruvate to assess metabolic remodeling in PAH
Study NCT05364775 — intervention group
Intervention type: OTHER
Intervention: Focus group
Description: Focus group
Study NCT05514002 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Fluzone Quadrivalent
Description: Intramuscular
Study NCT05514002 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Flublok Quadrivalent
Description: Intramuscular
Study NCT05780437 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AZD7442
Description: AZD8895 and AZD1061, known collectively as AZD7442, are two fully human neutralizing immunoglobulin G (IgG)-1 kappa monoclonal antibodies (mAb) that target two distinct epitopes on the receptor-binding domain of the spike protein of SARS-CoV- 2.
Study NCT05181852 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IP2015, dose 1
Description: Active
Study NCT05181852 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IP2015, dose 2
Description: Active
Study NCT05181852 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT05181852 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pregabalin
Description: Comparator